JPRN-UMIN000017529已完成未知
The study for adjunctive lithium for extended effect on antidepressant action of ketamine and its neural correlates. - Adjunctive treatment of lithium for extended action of ketamine. (ATLEK study)
试验速览
- 阶段
- 未知
- 状态
- 已完成
- 入组人数
- 80
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 69years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1.Patients with any clinically significant psychiatric disorder other than ICD-10 criteria for F32, F33, F31. 2.Patients with Lifetime history of mood-incongruent psychotic features based on DSM-IV-TR. 3.Patients judged clinically to be at serious and imminent suicidal or homicidal risk. 4.Imminent risk of other harm. 5.Patients with any organic brain disease. 6.Patients with unstable medical illness. 7.Patients treated with lithium within two weeks of consent. 8.Patients who are intolerant to Ketamine or Lithium because of reasons below; thyroid dysfunction, parathyroid dysfunction, renal dysfunction, atrio-ventricular block, epilepsy, uncontrolled hypertension, adverse events in using ketamine or lithium ever before. 9.Women who are pregnant or who wish to become pregnant during the research.
研究者
相似试验
撤回
不适用
Efficacy of Lithium as an Adjunctive Therapy for HIV associated neurocognitive impairment TrialHIV associated Mild Neurocognitive DisorderNeurological - Other neurological disordersInfection - Acquired immune deficiency syndrome (AIDS / HIV)Mental Health - Studies of normal psychology, cognitive function and behaviourACTRN12612000727842niversity of Melbourne100
进行中（未招募）
不适用
A randomised sequential trial of Lithium in amyotrophic lateral sclerosis - Lithium in ALSAmyotrophic lateral sclerosis (ALS) is a disease characterised by progressive degeneration of motor neurons in brain and spinal cord leading to muscle weakness. ALS can occur at anytime in adulthood. Muscle weakness gradually progresses. Approximately 50% of patients die within 3 years after onset of symptoms, usually as the result of respiratory failure. To date, only one drug, i.e. riluzole, has proven to extend survival in patients with ALS, but only by approximately 3 to 6 months.MedDRA version: 9.1Level: LLTClassification code 10052889Term: ALSEUCTR2008-002110-22-NLProf. dr L.H. van den Berg, UMC-Utrecht
招募中
2 期
A randomised sequential trial of Lithium in amyotrophic lateral sclerosismotor neuron diseaseamyotrophic lateral sclerosis (ALS)10029317NL-OMON31977niversitair Medisch Centrum Utrecht191
招募中
2 期
Effect of lithium carbonate on COVID-19IRCT20081019001369N5Mashhad University of Medical Sciences40
尚未招募
不适用
ithium trial bij ALSALSamyotrophic lateral sclerosisamyotrofische laterale scleroseNL-OMON20046Prof. dr. L.H. van den Berg, neurologist Dep. neurology, UMC-UtrechtHeidelberglaan 100/HP G03.2283584CX UtrechtTel: +31-88-7557939Fax: +31-30-2542100Email: L.H.vandenBerg@umcutrecht.nl191